These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 18028479

  • 41. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 42. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED.
    Am J Surg Pathol; 2007 Feb 12; 31(2):233-9. PubMed ID: 17255768
    [Abstract] [Full Text] [Related]

  • 43. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G.
    Best Pract Res Clin Haematol; 2014 Jun 12; 27(2):129-40. PubMed ID: 25189724
    [Abstract] [Full Text] [Related]

  • 44. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
    Gebauer N, Bernard V, Gebauer W, Feller AC, Merz H.
    Acta Haematol; 2013 Jun 12; 129(4):251-6. PubMed ID: 23343777
    [Abstract] [Full Text] [Related]

  • 45. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O, Levine RL.
    Leukemia; 2008 Oct 12; 22(10):1813-7. PubMed ID: 18754026
    [Abstract] [Full Text] [Related]

  • 46. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM, Thiele J.
    Pathobiology; 2007 Oct 12; 74(2):63-71. PubMed ID: 17587877
    [Abstract] [Full Text] [Related]

  • 47. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
    Kreft A, Kindler T, Springer E, Kirkpatrick CJ.
    Virchows Arch; 2011 Nov 12; 459(5):521-7. PubMed ID: 22006129
    [Abstract] [Full Text] [Related]

  • 48. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Nov 12; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 49. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
    Bojko P, Abenhardt W, Schnittger S, Haferlach T.
    Onkologie; 2009 Apr 12; 32(4):191-5. PubMed ID: 19372714
    [Abstract] [Full Text] [Related]

  • 50. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A, Büche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ.
    Acta Haematol; 2005 Apr 12; 113(2):137-43. PubMed ID: 15802893
    [Abstract] [Full Text] [Related]

  • 51. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J, Kvasnicka HM, Vardiman J.
    Best Pract Res Clin Haematol; 2006 Apr 12; 19(3):413-37. PubMed ID: 16781481
    [Abstract] [Full Text] [Related]

  • 52. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
    Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A.
    Leukemia; 2007 Sep 12; 21(9):1964-70. PubMed ID: 17581608
    [Abstract] [Full Text] [Related]

  • 53. JAK2-positive Philadelphia-negative myeloproliferative neoplasms.
    Sharma A, Buxi G, Marwah S, Yadav R.
    Indian J Pathol Microbiol; 2011 Sep 12; 54(1):117-20. PubMed ID: 21393891
    [Abstract] [Full Text] [Related]

  • 54. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC, de Cesare Quintero F, Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM, Visentainer JE.
    Blood Cells Mol Dis; 2016 Mar 12; 57():54-7. PubMed ID: 26852656
    [Abstract] [Full Text] [Related]

  • 55. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 12; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 56. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ, Juvonen E.
    Semin Thromb Hemost; 1997 Jun 12; 23(4):339-47. PubMed ID: 9263350
    [Abstract] [Full Text] [Related]

  • 57. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 12; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 58. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
    Tefferi A, Vainchenker W.
    J Clin Oncol; 2011 Feb 10; 29(5):573-82. PubMed ID: 21220604
    [Abstract] [Full Text] [Related]

  • 59. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 10; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [Abstract] [Full Text] [Related]

  • 60. [Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases].
    Sokolova MA, Khoroshko ND, Tsvetaeva NV, Semenova EA, Kaplanskaia IB, Frank GA, Misiurin AV.
    Ter Arkh; 2010 Jun 10; 82(12):47-51. PubMed ID: 21516739
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.